1. Ryan K. Shields and Doi Yohei. Penicillins and Betalactamase Inhibitors. In: Mandell, Dougles and Bennett’s Principles and Practice of InfectiousDiseases. 10th Ed, New York: Churchill Livin-
gstone; 2025: 263-2278.
2. Akova M, Kayaalp O. Beta-taklam Antibiyotikler I: Penisilinler. Tıbbi Farmakoloji. 10. Baskı, Ankara: Hacettepe Taş Kitapçılık Ltd. Şti.; 2002: 210-33.
3. Nilay Aksoy. Penisilinler. In Güncel Farmakoloji Fizyoloji Temelinde Hasta Odaklı Yaklaşım. 1. Baskı, Ankara: Güneş Tıp Kitapevleri. 2022:721-724.
4. Mutlu G, Öğenç D. Mikroorganizmalarda hücre yapısı. Ustaçelebi Ş. (ed.). Temel ve Klinik Mikrobiyoloji, Ankara: Güneş Kitabevi Ltd. Şti.: 1999: 7.
5. AU Spratt BG, Cromie KD. Penicillin-binding proteins of gram-negative bacteria. Rev Infect Dis. 1988;10(4):699.
6. Ghosh AS, Melquist AL, Young KD. Loss of O-antigen increases celi shape abnormalities in penicillin-binding protein mutants of Escherichia coli. FEMS MicrobiolLett. 2006: 263(2): 252-57.
7. Clinical and Laboratory Standards Institute (CLSI). M07 Performance Standards for Antimicrobial Susceptibility Testing. Yayın Tarihi: 19.03.2024, Erişim Tarihi: 3 Eylül, 2025 https://clsi.org/
shop/standards/m07/
8. http://www.tmc-online.org/EUCAST (Erişim tarihi: 12 Kasım 2026)
9. Söyletir G. EUCAST ve CLSI tercihleri: Türkiye’de nereye gitmeliyiz?. Ankem Derg 2013; 27 (Ek 2): 19-20.
10. Erdem H. Pahsa A. Antibiotic resistance in pathogenic Streptococcus pneumoniae isolates in Turkey. J Chemother. 2005: 17(1):25-30.
11. Thomson KS, Lister PD. Other beta-lactam antibiotics. In: Gorbach SL, Bartlett JG, Blacklow NR. InfectiousDiseases. 2nd Ed. Philadelp- hia, WB SaundersCo.; 2004: 204-7
12. Öztürk R. Penisilinler. Antibiyotikler. (Ed.) Leblebicioğlu H, Usluer G, Ulusoy S. Ankara: Bilimsel Tıp Yayınevi. 2008; 253-69.
13. Catherine L. Tooke, Philip Hinchliffe, Eilis C. Bragginton,et al. β-Lactamases and β-Lactamase Inhibitors in the 21st Century. Journal of Molecular Biology. 2019:43(18):3472-3500.
14. Sawa, Kooguchi and Moriyama. Molecular diversity of extended-spectrum β-lactamases and carbapenemases, and antimicrobial resistance. J Intensive Care. 2020;28:8:13.
15. Wilks D, Farrington M, Rubenstein D. TheInfectiousDiseases Manual. Oxford, Londoın, Edinburg, BlackwellScience Ltd. Malden, 1995; 297.
16. Arason VA. Sigurdsson JA, Erlendsdottir H. Gudmundsson S. Kristinsson KG. The role of antimicrobial use in the epidemiology of resistant pneumococci: A 10-year foIIow up. Microb Drug
Resist. 2006; 12(3): 169-76.
17. Ariffin H, Ai CL, Lee CL, Abdullah WA. Cefepime monotherapy for treatment of febrile neutropenia in children. J Pediatr Child Health. 2006; 42(12): 781-84.
18. Samoilenko VA, Amelina EL. Chuchalin AG. Effectiveness of the new carbapenem antibiotic, meropenem, in adult patients with mucovisciosis. Antibiot Khimioter. 1998:43(1): 24-7.
19. Johnson CA, Halstenson CE, Kelloway JS, et al: Single döşe pharmaco kinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 1992; 51:32-41.
20. Sorgel F, Kinzig M: The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 1993; 31:39-60.
21. Kern W, Kennedy SL, Sachdeva M, et al: Evaluation of piperacillin- tazobactam in experimental meningitis caused by a beta-lactamase producing strain of K1-positive Escherichiacoli. Anti-
microb Agents Chemother 1990; 34:697-701.
22. Maltezou HC, Nikolaidis P, Lebesii E, et al: Piperacillin/tazobactam versus cefotaxime plus metronidazole for treatment of children with intra abdominal infections requiring surgery. Eur J
Clin Microbiol InfectDis 2001; 20:643-646.
23. Kuck NA, Jacobus NV, Petersen PJ, et al: Comparative in vitroand in vivoactivities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
Antimicrob Agents Chemother 1989; 33:1964-1969.
24. Gin A, Dilay L, Karlowsky JA, et al: Piperacillin-tazobactam: a beta- lactam/beta-lactamase inhibitör combination. Expert Rev Anti Infect Ther 2007; 5:365-383.
25. Sader HS, Hsiung A, Fritsche TR, et al: Comparative activities of cefepime andpiperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL
phenotype. Diagn Microbiol InfectDis 2007; 57:341-344.
26. Gavin PJ, Suseno MT, Thomson Jr RB, et al. Clinicalcorrelation of the CLSI susceptibility breakpoint forpiperacillin-tazobactam against extended spectrum beta-lactamase producing Esche-
richia coli and Klebsiella species. Antimicrob Agents Chemother 2006; 50:2244-2247.